Marinus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MRNS)

$6.47 -0.01 (-0.15 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$6.48
Today's Range$6.30 - $6.60
52-Week Range$0.82 - $8.25
Volume469,400 shs
Average Volume1.20 million shs
Market Capitalization$261.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:MRNS
  • CUSIP: N/A
  • Web: www.marinuspharma.com
Debt:
  • Current Ratio: 17.92%
  • Quick Ratio: 17.92%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.09 per share
  • Price / Book: 5.94
Profitability:
  • Trailing EPS: ($0.93)
  • Net Income: ($28,640,000.00)
  • Return on Equity: -67.76%
  • Return on Assets: -55.65%
Misc:
  • Employees: 15
  • Outstanding Shares: 40,430,000
 

Frequently Asked Questions for Marinus Pharmaceuticals (NASDAQ:MRNS)

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings data on Tuesday, October, 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.02. View Marinus Pharmaceuticals' Earnings History.

Where is Marinus Pharmaceuticals' stock going? Where will Marinus Pharmaceuticals' stock price be in 2017?

1 Wall Street analysts have issued twelve-month price targets for Marinus Pharmaceuticals' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $11.00 in the next year. View Analyst Ratings for Marinus Pharmaceuticals.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest in the month of October. As of October 13th, there was short interest totalling 3,183,085 shares, an increase of 53.3% from the September 29th total of 2,076,679 shares. Based on an average trading volume of 2,062,293 shares, the short-interest ratio is presently 1.5 days. Currently, 13.8% of the company's shares are sold short.

Who are some of Marinus Pharmaceuticals' key competitors?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:

  • Christopher M. Cashman, Chairman of the Board, President, Chief Executive Officer (Age 59)
  • Lorianne K. Masuoka M.D., Chief Medical Officer (Age 55)
  • Edward F. Smith, Chief Financial Officer, Vice President, Treasurer, Secretary (Age 44)
  • Michael R. Dougherty, Director (Age 59)
  • Seth H. Z. Fischer, Director (Age 61)
  • Enrique J. Carrazana M.D., Independent Director (Age 54)
  • Timothy M. Mayleben, Independent Director (Age 56)
  • Jay P. Shepard, Independent Director (Age 59)

Who owns Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Granite Point Capital Management L.P. (6.64%), Jennison Associates LLC (3.97%), Perceptive Advisors LLC (3.59%), Iguana Healthcare Management LLC (0.43%), EAM Investors LLC (0.23%) and Citadel Advisors LLC (0.13%). Company insiders that own Marinus Pharmaceuticals stock include Anand Mehra and Vii Lp Canaan. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Who bought Marinus Pharmaceuticals stock? Who is buying Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Perceptive Advisors LLC, Jennison Associates LLC, Iguana Healthcare Management LLC, EAM Investors LLC, Citadel Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy Marinus Pharmaceuticals stock?

Shares of Marinus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of Marinus Pharmaceuticals stock can currently be purchased for approximately $6.47.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $261.58 million. The biopharmaceutical company earns ($28,640,000.00) in net income (profit) each year or ($0.93) on an earnings per share basis. Marinus Pharmaceuticals employs 15 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 170 N Radnor Chester Rd Ste 250, RADNOR, PA 19087-5279, United States. The biopharmaceutical company can be reached via phone at +1-484-8014670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (70.02% upside)

Consensus Price Target History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Price Target History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Analysts' Ratings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017JMP SecuritiesReiterated RatingOutperform$5.00 -> $11.00HighView Rating Details
10/3/2016Jefferies Group LLCReiterated RatingBuy$3.00N/AView Rating Details
6/28/2016Stifel NicolausReiterated RatingHoldN/AView Rating Details
6/14/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralN/AView Rating Details
6/14/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$14.00 -> $2.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Marinus Pharmaceuticals (NASDAQ:MRNS)

Earnings by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Earnings History by Quarter for Marinus Pharmaceuticals (NASDAQ MRNS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.17)($0.15)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.27)($0.21)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.32)($0.26)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.33)($0.31)ViewN/AView Earnings Details
11/3/2016Q3($0.43)($0.33)ViewN/AView Earnings Details
8/9/2016Q2($0.38)($0.46)ViewN/AView Earnings Details
5/2/2016Q1 2016($0.41)($0.37)ViewN/AView Earnings Details
3/7/2016Q416($0.38)($0.45)ViewN/AView Earnings Details
10/29/2015Q3 2015($0.51)($0.35)ViewN/AView Earnings Details
8/4/2015Q2 2015($0.51)($0.37)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.47)($0.50)ViewN/AView Earnings Details
11/13/2014Q3 14($0.50)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)
2017 EPS Consensus Estimate: ($0.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Marinus Pharmaceuticals (NASDAQ:MRNS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Marinus Pharmaceuticals (NASDAQ MRNS)

Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 19.04%
Insider Trades by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Insider Trades by Quarter for Marinus Pharmaceuticals (NASDAQ MRNS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Anand MehraMajor ShareholderSell750,683$1.39$1,043,449.37View SEC Filing  
8/8/2016Vii Lp CanaanMajor ShareholderSell149,154$1.50$223,731.00View SEC Filing  
8/4/2016Vii Lp CanaanMajor ShareholderSell145,583$1.50$218,374.50View SEC Filing  
7/29/2016Vii Lp CanaanMajor ShareholderSell24,540$1.71$41,963.40View SEC Filing  
7/27/2016Vii Lp CanaanMajor ShareholderSell20,589$1.81$37,266.09View SEC Filing  
7/26/2016Vii Lp CanaanMajor ShareholderSell20,380$1.81$36,887.80View SEC Filing  
7/25/2016Vii Lp CanaanMajor ShareholderSell270,750$1.90$514,425.00View SEC Filing  
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Marinus Pharmaceuticals (NASDAQ MRNS)

Source:
DateHeadline
Marinus Pharmaceuticals, Inc. (MRNS) Releases  Earnings ResultsMarinus Pharmaceuticals, Inc. (MRNS) Releases Earnings Results
www.americanbankingnews.com - November 1 at 11:36 AM
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 6:26 AM
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 6:26 AM
Marinus Pharmaceuticals posts 3Q lossMarinus Pharmaceuticals posts 3Q loss
finance.yahoo.com - November 1 at 6:26 AM
Marinus Pharmaceuticals posts 3Q lossMarinus Pharmaceuticals posts 3Q loss
finance.yahoo.com - November 1 at 6:26 AM
Are Marinus Pharmaceuticals Inc’s (MRNS) Interest Costs Too High?Are Marinus Pharmaceuticals Inc’s (MRNS) Interest Costs Too High?
finance.yahoo.com - October 31 at 6:31 AM
First Week of MRNS December 15th Options TradingFirst Week of MRNS December 15th Options Trading
www.thestreet.com - October 27 at 8:09 AM
First Week of MRNS December 15th Options TradingFirst Week of MRNS December 15th Options Trading
www.thestreet.com - October 27 at 8:09 AM
Marinus Pharmaceuticals, Inc. (MRNS) Short Interest Up 53.3% in OctoberMarinus Pharmaceuticals, Inc. (MRNS) Short Interest Up 53.3% in October
www.americanbankingnews.com - October 27 at 1:40 AM
Marinus Pharmaceuticals, Inc. (MRNS) Scheduled to Post Quarterly Earnings on WednesdayMarinus Pharmaceuticals, Inc. (MRNS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 5:24 AM
Todays Research Report Coverage on Biotech Stocks -- Marinus Pharma, NewLink Genetics, Akcea Therapeutics, and ... - PR Newswire (press release)Today's Research Report Coverage on Biotech Stocks -- Marinus Pharma, NewLink Genetics, Akcea Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - October 2 at 11:35 AM
Amphastar Pharmaceuticals (AMPH) vs. Marinus Pharmaceuticals (MRNS) Head to Head SurveyAmphastar Pharmaceuticals (AMPH) vs. Marinus Pharmaceuticals (MRNS) Head to Head Survey
www.americanbankingnews.com - October 1 at 2:32 AM
Marinus Pharmaceuticals (MRNS) and Its Rivals Head to Head ReviewMarinus Pharmaceuticals (MRNS) and Its Rivals Head to Head Review
www.americanbankingnews.com - September 30 at 2:24 PM
Main Line biopharm firm completes $40.3M stock sale - Philadelphia Business JournalMain Line biopharm firm completes $40.3M stock sale - Philadelphia Business Journal
www.bizjournals.com - September 22 at 6:06 AM
Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare ConferenceMarinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 6:06 AM
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter’s option to purchase additional sharesMarinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter’s option to purchase additional shares
finance.yahoo.com - September 20 at 6:31 AM
Marinus Pharmaceuticals (MRNS) & Its Peers Critical ReviewMarinus Pharmaceuticals (MRNS) & Its Peers Critical Review
www.americanbankingnews.com - September 18 at 2:30 PM
Comparing Marinus Pharmaceuticals (MRNS) & The CompetitionComparing Marinus Pharmaceuticals (MRNS) & The Competition
www.americanbankingnews.com - September 16 at 8:24 PM
Marinus Pharma (MRNS) Prices 9.33M Common Stock Offering at $3.75/ShareMarinus Pharma (MRNS) Prices 9.33M Common Stock Offering at $3.75/Share
www.streetinsider.com - September 16 at 8:09 PM
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 16 at 6:35 AM
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common StockMarinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 16 at 6:35 AM
Marinus Pharmaceuticals Announces Public Offering of Common Stock - GlobeNewswire (press release)Marinus Pharmaceuticals Announces Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 15 at 2:21 AM
Todays Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical IndustriesToday's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries
finance.yahoo.com - September 14 at 4:13 PM
Marinus Pharmaceuticals Announces Public Offering of Common StockMarinus Pharmaceuticals Announces Public Offering of Common Stock
finance.yahoo.com - September 14 at 4:13 PM
Pre-Market Most Active for Sep 12, 2017 : TEVA, AEG, SAGE, AAPL, TVIX, MT, NOK, AZN, CS, MRNS, ICPT, KWEB - NasdaqPre-Market Most Active for Sep 12, 2017 : TEVA, AEG, SAGE, AAPL, TVIX, MT, NOK, AZN, CS, MRNS, ICPT, KWEB - Nasdaq
www.nasdaq.com - September 13 at 6:41 AM
Marinus Stock Surges on Successful Phase II Epilepsy Study - NasdaqMarinus Stock Surges on Successful Phase II Epilepsy Study - Nasdaq
www.nasdaq.com - September 13 at 6:41 AM
Marinus Pharmaceuticals, Inc. (MRNS) Earns Outperform Rating from JMP SecuritiesMarinus Pharmaceuticals, Inc. (MRNS) Earns Outperform Rating from JMP Securities
www.americanbankingnews.com - September 12 at 9:30 AM
Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for GanaxoloneMarinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
finance.yahoo.com - September 12 at 2:45 AM
Marinus Pharma Wins Big With Mid-Stage Epilepsy StudyMarinus Pharma Wins Big With Mid-Stage Epilepsy Study
finance.yahoo.com - September 12 at 2:45 AM
Todays Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks TherapeuticsToday's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks Therapeutics
finance.yahoo.com - August 4 at 5:25 AM
Marinus Pharmaceuticals, Inc. (MRNS) Releases Quarterly  Earnings Results, Beats Expectations By $0.06 EPSMarinus Pharmaceuticals, Inc. (MRNS) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - August 2 at 3:28 PM
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:06 AM
Marinus Pharmaceuticals posts 2Q lossMarinus Pharmaceuticals posts 2Q loss
finance.yahoo.com - August 2 at 6:06 AM
Comparing Marinus Pharmaceuticals (NASDAQ:MRNS) & BioDelivery Sciences International (BDSI)Comparing Marinus Pharmaceuticals (NASDAQ:MRNS) & BioDelivery Sciences International (BDSI)
www.americanbankingnews.com - July 22 at 8:02 AM
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in USMarinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
finance.yahoo.com - July 1 at 2:33 AM
Marinus Pharma (MRNS) Says FDA Grants Orphan Drug ... - StreetInsider.comMarinus Pharma (MRNS) Says FDA Grants Orphan Drug ... - StreetInsider.com
www.streetinsider.com - June 30 at 1:51 AM
Marinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPD - StreetInsider.comMarinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPD - StreetInsider.com
www.streetinsider.com - June 28 at 10:08 AM
Marinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPDMarinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPD
www.streetinsider.com - June 27 at 11:47 PM
How These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma - PR Newswire (press release)How These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma - PR Newswire (press release)
www.prnewswire.com - May 18 at 8:24 AM
Marinus Pharma (MRNS) to Present Ganaxolone DATA at AAN - StreetInsider.comMarinus Pharma (MRNS) to Present Ganaxolone DATA at AAN - StreetInsider.com
www.streetinsider.com - April 20 at 9:55 AM
Marinus Pharma (MRNS) to Present Ganaxolone DATA at AANMarinus Pharma (MRNS) to Present Ganaxolone DATA at AAN
www.streetinsider.com - April 18 at 10:19 AM
Marinus Pharma (MRNS) Announces Lorianne Masuoka as New Chief Medical Officer - StreetInsider.comMarinus Pharma (MRNS) Announces Lorianne Masuoka as New Chief Medical Officer - StreetInsider.com
www.streetinsider.com - April 13 at 8:32 AM
Ultragenyxs’ Seizure Drug Fails StudyUltragenyxs’ Seizure Drug Fails Study
www.investopedia.com - March 23 at 7:09 PM
MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - March 22 at 6:44 PM
MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual ReportMARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 10:16 AM
Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus PharmaTechnical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma
www.bizjournals.com - February 28 at 10:13 AM
Marinus Pharma (MRNS) Says Study Shows Ganaxolone Reduces ... - StreetInsider.comMarinus Pharma (MRNS) Says Study Shows Ganaxolone Reduces ... - StreetInsider.com
www.streetinsider.com - February 14 at 8:15 PM
MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - February 8 at 7:32 PM
Marinus Appoints Michael R. Dougherty to its Board of Directors - GlobeNewswire (press release)Marinus Appoints Michael R. Dougherty to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 1 at 7:43 PM
Form 8-K MARINUS PHARMACEUTICALS For: Jan 23Form 8-K MARINUS PHARMACEUTICALS For: Jan 23
www.streetinsider.com - January 24 at 7:23 PM

Social Media

Financials

Chart

Marinus Pharmaceuticals (NASDAQ MRNS) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.